journal
MENU ▼
Read by QxMD icon Read
search

Lancet Haematology

journal
https://www.readbyqxmd.com/read/30201588/splanchnic-vein-thrombosis-what-are-the-long-term-risks
#1
Sam Schulman
No abstract text is available yet for this article.
September 7, 2018: Lancet Haematology
https://www.readbyqxmd.com/read/30201587/risk-of-bleeding-and-arterial-cardiovascular-events-in-patients-with-splanchnic-vein-thrombosis-in-denmark-a-population-based-cohort-study
#2
Kirstine Kobberøe Søgaard, Kasper Adelborg, Bianka Darvalics, Erzsébet Horváth-Puhó, Jan Beyer-Westendorf, Walter Ageno, Henrik Toft Sørensen
BACKGROUND: Little is known about adverse events following splanchnic vein thrombosis. Venous thromboembolism has been associated with increased risks of bleeding and arterial cardiovascular events. To learn more about the clinical course of splanchnic vein thrombosis, we examined the risks of bleeding and arterial cardiovascular events in patients with the disease, and compared them with the risks in patients with deep vein thrombosis (DVT) or pulmonary embolism (PE) and individuals from the general population...
September 7, 2018: Lancet Haematology
https://www.readbyqxmd.com/read/30172346/molecular-monitoring-of-adenovirus-reactivation-in-faeces-after-haematopoietic-stem-cell-transplantation-to-predict-systemic-infection-a-retrospective-cohort-study
#3
Ryan Malcolm Hum, David Deambrosis, Su Han Lum, Emma Davies, Denise Bonney, Malcolm Guiver, Andrew Turner, Robert Francis Wynn, Prashant Hiwarkar
BACKGROUND: Faecal shedding of adenovirus following allogeneic haematopoietic stem-cell transplantation (HSCT) is an early sign of loss of immune control over adenovirus, but there is no consensus on the role of monitoring of faecal adenoviral load by serial testing. We investigated whether serial faecal PCR monitoring could predict the risk of adenoviraemia and survival outcomes after HSCT. METHODS: We did a retrospective cohort study at the Royal Manchester Children's Hospital, Manchester, UK, of patients who had received their first allogeneic HSCT between Feb 1, 2003, and Sept 1, 2016, and adenovirus infection recorded in their medical records...
September 2018: Lancet Haematology
https://www.readbyqxmd.com/read/30172345/lenalidomide-in-combination-with-r-chop-r2-chop-as-first-line-treatment-of-patients-with-high-tumour-burden-follicular-lymphoma-a-single-arm-open-label-phase-2-study
#4
Hervé Tilly, Franck Morschhauser, Olivier Casasnovas, Thierry Jo Molina, Pierre Feugier, Steven Le Gouill, Corinne Haioun, Olivier Tournilhac, Reda Bouabdallah, Jean Gabarre, Thierry Lamy, José Cabeçadas, Stéphanie Becker, Fabrice Jardin, Nicolas Mounier, Gilles Salles
BACKGROUND: Immunochemotherapy with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) is a standard front-line treatment for follicular lymphoma. The combination of lenalidomide and rituximab has shown high efficacy in relapsed or refractory and untreated follicular lymphoma. We aimed to evaluate the safety and activity of the combination of lenalidomide and R-CHOP (R2-CHOP) in previously untreated patients with high burden follicular lymphoma. METHODS: This single-arm, open-label, multicentre, phase 2 trial was done in 16 hospitals in France, all of which were Lymphoma Study Association (LYSA) sites...
September 2018: Lancet Haematology
https://www.readbyqxmd.com/read/30172344/artificial-intelligence-for-cancer-associated-thrombosis-risk-assessment-author-s-reply
#5
LETTER
Alok A Khorana
No abstract text is available yet for this article.
September 2018: Lancet Haematology
https://www.readbyqxmd.com/read/30172343/artificial-intelligence-for-cancer-associated-thrombosis-risk-assessment
#6
LETTER
Patrizia Ferroni, Mario Roselli, Fabio M Zanzotto, Fiorella Guadagni
No abstract text is available yet for this article.
September 2018: Lancet Haematology
https://www.readbyqxmd.com/read/30172342/should-an-hla-matched-donor-still-be-considered-the-perfect-donor
#7
Richard J Jones, Mary M Horowitz
No abstract text is available yet for this article.
September 2018: Lancet Haematology
https://www.readbyqxmd.com/read/30172341/predictive-value-of-faecal-adenoviral-load-for-viraemia
#8
Genovefa Papanicolaou
No abstract text is available yet for this article.
September 2018: Lancet Haematology
https://www.readbyqxmd.com/read/30172340/lenalidomide-and-r-chop-in-follicular-lymphoma-where-do-we-go-from-here
#9
Leo I Gordon
No abstract text is available yet for this article.
September 2018: Lancet Haematology
https://www.readbyqxmd.com/read/30172339/the-undocumented-struggle-with-emergency-only-dialysis
#10
EDITORIAL
The Lancet Haematology
No abstract text is available yet for this article.
September 2018: Lancet Haematology
https://www.readbyqxmd.com/read/30122330/advancing-haematological-research-and-clinical-practice-a-call-for-papers-for-ash-2018
#11
Jiaying Tan, Vania Wisdom, David Collingridge
No abstract text is available yet for this article.
September 2018: Lancet Haematology
https://www.readbyqxmd.com/read/30115541/cladribine-and-low-dose-cytarabine-alternating-with-decitabine-as-front-line-therapy-for-elderly-patients-with-acute-myeloid-leukaemia-a-phase-2-single-arm-trial
#12
Tapan M Kadia, Jorge Cortes, Farhad Ravandi, Elias Jabbour, Marina Konopleva, Christopher B Benton, Jan Burger, Koji Sasaki, Gautam Borthakur, Courtney D DiNardo, Naveen Pemmaraju, Naval Daver, Alessandra Ferrajoli, Xuemei Wang, Keyur Patel, Jeffrey L Jorgensen, Sa Wang, Susan O'Brien, Sherry Pierce, Carla Tuttle, Zeev Estrov, Srdan Verstovsek, Guillermo Garcia-Manero, Hagop Kantarjian
BACKGROUND: Front-line therapy for elderly or unfit patients with acute myeloid leukaemia (AML) remains unsatisfactory with poor outcomes and excessive toxicity. We studied a new low-intensity regimen of cladribine combined with low-dose cytarabine alternating with decitabine, aimed at improving outcomes in this population. Based on our previous experience, we hypothesised that this combination would be safe and more effective than current approaches with hypomethylating agents. METHODS: In this single-arm, open-label, single-centre phase 2 study, we enrolled patients aged 60 years or older with previously untreated AML or high-risk myelodysplastic syndrome who had adequate organ function and an Eastern Cooperative Oncology Group performance status of 2 or less...
September 2018: Lancet Haematology
https://www.readbyqxmd.com/read/30115540/blurring-lines-between-treatment-intensity-and-patient-fitness-in-elderly-people-with-aml
#13
Norbert Vey
No abstract text is available yet for this article.
September 2018: Lancet Haematology
https://www.readbyqxmd.com/read/30072146/assessment-of-asc-specks-as-a-putative-biomarker-of-pyroptosis-in-myelodysplastic-syndromes-an-observational-cohort-study
#14
Ashley A Basiorka, Kathy L McGraw, Farnoosh Abbas-Aghababazadeh, Amy F McLemore, Nicole D Vincelette, Grace A Ward, Erika A Eksioglu, David A Sallman, Najla Al Ali, Eric Padron, Javier Pinilla-Ibarz, Rami Komrokji, Erico Masala, Valeria Santini, Olivier Kosmider, Michaela Fontenay, Pierre Fenaux, Lubomir Sokol, Sheng Wei, Brooke Fridley, Alan F List
BACKGROUND: NLRP3 inflammasome-directed pyroptotic cell death drives ineffective haemopoiesis in myelodysplastic syndromes. During inflammasome assembly, the apoptosis-associated speck-like protein containing a CARD (PYCARD, commonly known as ASC) adaptor protein polymerises into large, filamentous clusters termed ASC specks that are released upon cytolysis. Specks are resistant to proteolytic degradation because of their prion-like structure, and therefore might serve as a biomarker for pyroptotic cell death in myelodysplastic syndromes...
September 2018: Lancet Haematology
https://www.readbyqxmd.com/read/30072145/asc-specks-a-biomarker-for-myelodysplastic-syndromes
#15
Dominik Wolf, Eicke Latz
No abstract text is available yet for this article.
September 2018: Lancet Haematology
https://www.readbyqxmd.com/read/30078408/rituximab-and-the-risk-of-transformation-of-follicular-lymphoma-a-retrospective-pooled-analysis
#16
Massimo Federico, María Dolores Caballero Barrigón, Luigi Marcheselli, Vittoria Tarantino, Martina Manni, Clementine Sarkozy, Sara Alonso-Álvarez, Marielle Wondergem, Guillaume Cartron, Armando Lopez-Guillermo, Djamila Issa, Franck Morschhauser, Miguel Alcoceba, Eva Kimby, Chiara Rusconi, Martine Chamuleau, Harald Holte, Sandra Lockmer, Silvia Montoto, Maria Gomes da Silva, Igor Aurer, Emanuele Zucca, Ewa Paszkiewicz-Kozik, Carla Minoia, Tetiana Skrypets, Yngvild Nuvin Blaker, Gilles Salles, Bertrand Coiffier
BACKGROUND: Histological transformation of follicular lymphoma to aggressive lymphoma is a serious event with a substantial effect on patient outcome. The aim of the Aristotle study was to assess the effect of rituximab on the risk of histological transformation and its outcome. METHODS: 11 cooperative groups or institutions across Europe contributed data to this study. Eligible patients (≥18 years) had histologically confirmed follicular lymphoma grade 1, 2, or 3a, diagnosed between Jan 2, 1997, and Dec 20, 2013...
August 2018: Lancet Haematology
https://www.readbyqxmd.com/read/30078407/rituximab-as-a-first-step-in-tackling-transformation
#17
Jessica Okosun, Robert Kridel, Jude Fitzgibbon
No abstract text is available yet for this article.
August 2018: Lancet Haematology
https://www.readbyqxmd.com/read/30075833/risk-of-second-primary-cancer-following-myeloid-neoplasia-and-risk-of-myeloid-neoplasia-as-second-primary-cancer-a-nationwide-observational-follow-up-study-in-sweden
#18
Subhayan Chattopadhyay, Guoqiao Zheng, Amit Sud, Hongyao Yu, Kristina Sundquist, Jan Sundquist, Asta Försti, Akseli Hemminki, Richard Houlston, Kari Hemminki
BACKGROUND: Although advances in the treatment of myeloid neoplasms have led to improved patient survival, this improvement has been accompanied by an increased risk of second primary cancer (ie, the risk of another cancer after myeloid neoplasia). We aimed to assess bi-directional associations between myeloid cancers and other cancers-ie, development of second primary cancer in patients who have previously had myeloid cancer, and risks of myeloid neoplasia in patients who have previously had another cancer-to provide insight into possible mechanisms beyond side-effects of treatment and shared risk factors...
August 2018: Lancet Haematology
https://www.readbyqxmd.com/read/30075832/23-rd-european-hematology-association-congress
#19
Lan-Lan Smith
No abstract text is available yet for this article.
August 2018: Lancet Haematology
https://www.readbyqxmd.com/read/30075831/secondary-primary-cancers-before-and-after-myeloid-neoplasia-a-two-way-street
#20
Guillermo Garcia-Manero
No abstract text is available yet for this article.
August 2018: Lancet Haematology
journal
journal
49595
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"